CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.

ABSTRACT:

Background

Dolutegravir is associated with more weight gain than efavirenz. Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART).

Methods

We studied ART-naive participants from the ADVANCE study randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emtricitabine/TDF arms. We compared changes in weight and regional fat on DXA from baseline to week 48 between CYP2B6 metabolizer genotypes in the efavirenz arm, and with the dolutegravir arm.

Results

There were 342 participants in the dolutegravir arm and 168 in the efavirenz arm who con

SUBMITTER: Griesel R 

PROVIDER: S-EPMC8653639 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature